1.97 0.05 (2.6%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.46 | 1-year : | 2.82 |
Resists | First : | 2.11 | Second : | 2.42 |
Pivot price | 2.01 ![]() |
|||
Supports | First : | 1.62 | Second : | 1.34 |
MAs | MA(5) : | 1.95 ![]() |
MA(20) : | 1.96 ![]() |
MA(100) : | 2.62 ![]() |
MA(250) : | 11.33 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 39.5 ![]() |
D(3) : | 40.1 ![]() |
RSI | RSI(14): 50.9 ![]() |
|||
52-week | High : | 23.71 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AMLX ] has closed above bottom band by 44.1%. Bollinger Bands are 82.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 82 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.98 - 1.99 | 1.99 - 2 |
Low: | 1.89 - 1.9 | 1.9 - 1.91 |
Close: | 1.95 - 1.97 | 1.97 - 1.99 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
Swiss National Bank Raises Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Wed, 24 Jul 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Wed, 24 Jul 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Hold” by Brokerages - Defense World
Wed, 10 Jul 2024
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript - Seeking Alpha
Tue, 09 Jul 2024
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide - Business Wire
Fri, 10 May 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 68 (M) |
Shares Float | 52 (M) |
Held by Insiders | 14.2 (%) |
Held by Institutions | 88.4 (%) |
Shares Short | 4,570 (K) |
Shares Short P.Month | 7,570 (K) |
EPS | -1.08 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.76 |
Profit Margin | -17.9 % |
Operating Margin | -137.8 % |
Return on Assets (ttm) | -12.4 % |
Return on Equity (ttm) | -21 % |
Qtrly Rev. Growth | 24.1 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 5.85 |
EBITDA (p.s.) | -1.18 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 17 (M) |
Levered Free Cash Flow | 35 (M) |
PE Ratio | -1.85 |
PEG Ratio | 0 |
Price to Book value | 0.41 |
Price to Sales | 0.33 |
Price to Cash Flow | 8.11 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |